Shockwave Announces Pricing of Public Offering of Common Stock

SANTA CLARA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (a??Shockwavea??) (Nasdaq: SWAV) today announced the pricing of its public offering of 2,481,781 shares of its common stock at a price to the public of $36.25 per share. All of the shares are being offered by Shockwave. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable byA Shockwave, are expected to beA approximately $90.0 million. The offering is scheduled to close onA November 19, 2019, subject to the satisfaction of customary closing conditions. The underwriters for the offering also have a 30-day option to purchase up to an additional 372,267 shares ofA Shockwavea??sA common stock at the price to the public, less underwriting discounts and commissions. Shockwavea??s common stock is listed on the Nasdaq Global Select Market under the ticker symbol a??SWAV.a??
Morgan Stanley and BofA Securities are acting as joint lead book-running managers for the offering. Wells Fargo Securities and Canaccord Genuity are acting as co-managers for the offering.Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on November 14, 2019. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255a??0001, Attention: Prospectus Department, or by email at press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which it refers to as Intravascular Lithotripsy (a??IVLa??). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Май 2022    »